Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | GLA | P06280 | 1/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.62 |
| ▸ | CTSL | P07711 | 3/20 | 0.61 |
| ▸ | CTSS | P25774 | 2/20 | 0.57 |
| ▸ | CTSK | P43235 | 2/20 | 0.57 |
| ▸ | CTSB | P07858 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.55 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16515824 | 1.00 | GAA (0.67) | GAARAB9AALDH1A1LMNAGLA | |
| SCHEMBL1793176 | 0.93 | GAA (0.76) | GAARAB9AALDH1A1LMNAGLA | |
| SCHEMBL2461492 | 0.93 | GAA (0.76) | GAARAB9AALDH1A1LMNAGLA | |
| SCHEMBL31206887 | 0.93 | GAA (0.76) | GAARAB9AALDH1A1LMNAGLA | |
| SCHEMBL3928164 | 0.90 | LNPEP (0.67) | GAARAB9AALDH1A1LMNAGLA | |
| SCHEMBL3928165 | 0.90 | LNPEP (0.67) | GAARAB9AALDH1A1LMNAGLA | |
| SCHEMBL6030105 | 0.89 | GAA (0.68) | GAARAB9AALDH1A1LMNAGLA | |
| SCHEMBL27761117 | 0.89 | CTSL (0.62) | GAARAB9AALDH1A1LMNAGLA | |
| SCHEMBL7613514 | 0.89 | RAB9A (0.64) | GAARAB9AALDH1A1LMNAGLA | |
| SCHEMBL5312462 | 0.89 | NOS3 (0.61) | GAARAB9AALDH1A1LMNAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017059759-A1 | PROCESS FOR PREPARATION OF N-BOC BIPHENYL ALANINOL | CHIRAL QUEST (SUZHOU) CO., LTD. (CN) | 2017-04-13 | — | — | WO | disclosed |
| EP-3119742-A1 | SYNTHESIS OF BIPHENYLALANINOL VIA NOVEL INTERMEDIATES | DPX Holdings B.V. (NL) | 2017-01-25 | — | — | EP | disclosed |
| US-20160200665-A1 | SYNTHESIS OF BIPHENYLALANINOL VIA NOVEL INTERMEDIATES | DPX HOLDINGS B.V. (NL) | 2016-07-14 | — | — | US | disclosed |
| US-20160200665-A1 | SYNTHESIS OF BIPHENYLALANINOL VIA NOVEL INTERMEDIATES | DPX HOLDINGS B.V. (NL) | 2016-07-14 | — | — | US | disclosed |
| US-20160200665-A1 | SYNTHESIS OF BIPHENYLALANINOL VIA NOVEL INTERMEDIATES | DPX HOLDINGS B.V. (NL) | 2016-07-14 | — | — | US | disclosed |
| US-9139515-B2 | Synthesis of R-biphenylalaninol | DPX HOLDINGS B.V. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9139515-B2 | Synthesis of R-biphenylalaninol | DPX HOLDINGS B.V. (US) | 2015-09-22 | — | — | US | disclosed |
| WO-2015024991-A1 | SYNTHESIS OF BIPHENYLALANINOL VIA NOVEL INTERMEDIATES | DPX HOLDINGS B.V. (NL) | 2015-02-26 | — | — | WO | disclosed |
| WO-2015024991-A1 | SYNTHESIS OF BIPHENYLALANINOL VIA NOVEL INTERMEDIATES | DPX HOLDINGS B.V. (NL) | 2015-02-26 | — | — | WO | disclosed |
| US-20140296559-A1 | SYNTHESIS OF R-BIPHENYLALANINOL | DSM FINE CHEMICALS AUSTRIA NFG. GMBH & CO KG (AT) | 2014-10-02 | — | — | US | disclosed |
| US-20140296559-A1 | SYNTHESIS OF R-BIPHENYLALANINOL | DSM FINE CHEMICALS AUSTRIA NFG. GMBH & CO KG (AT) | 2014-10-02 | — | — | US | disclosed |
| WO-2013026773-A1 | SYNTHESIS OF R-BIPHENYLALANINOL | DSM IP ASSETS B.V. (NL) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296559-A1 | SYNTHESIS OF R-BIPHENYLALANINOL | CYP2B6, CYP2A6, CYP2D6 | GAA 680/4885RAB9A 361/4885ALDH1A1 219/4885 |
| US-20160200665-A1 | SYNTHESIS OF BIPHENYLALANINOL VIA NOVEL INTERMEDIATES | CYP1B1, UGT1A1, UGT2B7 | GAA 310/4885RAB9A 668/4885ALDH1A1 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.